Literature DB >> 8087213

[Severe poisoning risk linked to intravenous administration of quinine].

E Jacqz-Aigrain1, S Bennasr, L Desplanques, A Peralma, F Beaufils.   

Abstract

BACKGROUND: High concentrations of quinine, the drug of choice for severe malaria, are toxic to the cardiovascular system, producing hypotension and abnormal myocardial conduction. CASE REPORTS: Five children, aged 14 months to 13 years, were admitted because of fever that appeared a few days after their return from an area in which malaria was endemic. Examination of a thick blood film showed Plasmodium falciparum. They were given quinine intravenously. Four children developed a seizure that recurred in three of them; the fifth child suffered from headache, buzzing in the ears and vision anomalies. Four children rapidly developed hypotension followed by cardiac arrest. All children had abnormal ECG. Retrospective study of the instructions given for quinine administration showed that they were inexplicit and were responsible for incorrect dilution of the drug. Four of the five children recovered completely. The fifth child developed ventricular tachycardia followed by bradycardia that did not respond to resuscitation.
CONCLUSION: Major errors can be made in prescribing intravenous quinine. This type of treatment must be carefully monitored and is only indicated in severe forms of malaria, which our patients were not suffering from.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8087213

Source DB:  PubMed          Journal:  Arch Pediatr        ISSN: 0929-693X            Impact factor:   1.180


  2 in total

Review 1.  High first dose quinine regimen for treating severe malaria.

Authors:  A Lesi; M Meremikwu
Journal:  Cochrane Database Syst Rev       Date:  2004

2.  Fever accentuates transmural dispersion of repolarization and facilitates development of early afterdepolarizations and torsade de pointes under long-QT Conditions.

Authors:  Alexander Burashnikov; Wataru Shimizu; Charles Antzelevitch
Journal:  Circ Arrhythm Electrophysiol       Date:  2008-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.